Chirality and neuropsychiatric drugs: an update on stereoselective disposition and clinical pharmacokinetics of bupropion

References

• Alkadi H, Jbeily R. (2017). Role of chirality in drugs: an overview. Infect Disord Drug Targets 2017. [Epub ahead of print]. doi: 10.2174/1871526517666170329123845
   PubMedGoogle Scholar
• Ascher JA, Cole JO, Colin JN, et al. (1995). Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 56:395–401
   PubMed Web of Science ®Google Scholar
• Baker GB, Prior T. (2002). Stereochemistry and drug efficacy and development: relevance of chirality to antidepressant and antipsychotic drugs. Ann Med 34:537–43
   PubMed Web of Science ®Google Scholar
• Billups SJ, Delate T, Dugan D. (2009). Evaluation of risk factors for elevated tricyclic antidepressant plasma concentrations. Pharmacoepidemiol Drug Saf 18:253–7
   PubMed Web of Science ®Google Scholar
• Carroll FI, Blough BE, Mascarella SW, et al. (2014). Bupropion and bupropion analogs as treatments for CNS disorders. Adv Pharmacol 69:177–216
   PubMedGoogle Scholar
• Coles R, Kharasch ED. (2008). Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes. Pharm Res 25:1405–11
   PubMed Web of Science ®Google Scholar
• Dwoskin LP, Rauhut AS, King-Pospisil KA, et al. (2006). Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev 12:178–207
   PubMedGoogle Scholar
• Fabre J, Louis F, McLendon DM. (1978). Double-blind placebo-controlled study of bupropion hydrochloride (Wellbutrin®) in the treatment of depressed in-patients. Curr Ther Res 23:393
   Web of Science ®Google Scholar
• Fang QK, Han Z, Grover P, et al. (2000). Rapid access to enantiopure bupropion and its major metabolite by stereospecific nucleophilic substitution on an α-ketotriflate. Tetrahedron: Asymmetry 11:3659–63
   Web of Science ®Google Scholar
• Fann WE, Schroeder DH, Metha NBS, et al. (1978). Clinical trial of bupropion HCl in treatment of depression. Curr Ther Res 23:222
   Web of Science ®Google Scholar
• Faucette SR, Hawke RL, Lecluyse EL, et al. (2000). Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:1222–30
   PubMed Web of Science ®Google Scholar
• Faucette SR, Wang H, Hamilton GA, et al. (2004). Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos 32:348–58
   PubMed Web of Science ®Google Scholar
• Ferris RM, Cooper BR. (1993). Mechanism of antidepressant activity of bupropion. J Clin Psychiatry Monograph 11:2–14
   Web of Science ®Google Scholar
• Ferris RM, White HL, Cooper BR, et al. (1981). Some neurochemical properties of a new antidepressant, bupropion hydrochloride (Wellbutrin®). Drug Dev Res 1:21–35
   Web of Science ®Google Scholar
• Findlay JW, Van Wyck Fleet J, Smith PG, et al. (1981). Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects. Eur J Clin Pharmacol 21:127–35
   PubMed Web of Science ®Google Scholar
• Foley KF, DeSanty KP, Kast RE. (2006). Bupropion: pharmacology and therapeutic applications. Expert Rev Neurother 6:1249–65
   PubMed Web of Science ®Google Scholar
• Gao LC1, Huang X, Tan ZR, et al. (2012). The effects of sodium ferulate on the pharmacokinetics of bupropion and its active metabolite in healthy men. Eur Rev Med Pharmacol Sci 16:1192–6
   PubMed Web of Science ®Google Scholar
• Gheldiu AM, Popa A, Neag M, et al. (2016). Assessment of a potential pharmacokinetic interaction between nebivolol and bupropion in healthy volunteers. Pharmacology 98:190–8
   PubMed Web of Science ®Google Scholar
• Golden RN, Rudorfer MV, Sherer MA, et al. (1988a). Bupropion in depression, 1: biochemical effects and clinical response. Arch Gen Psychiatry 45:139–43
   PubMed Web of Science ®Google Scholar
• Golden RN, De Vane CL, Laizure SC, et al. (1988b). Bupropion in depression. II. The role of metabolites in clinical outcome. Arch Gen Psychiatry 45:145–9
   PubMed Web of Science ®Google Scholar
• Gufford BT, Lu JB, Metzger IF, et al. (2016). Stereoselective glucuronidation of bupropion metabolites in vitro and in vivo. Drug Metab Dispos 44:544–53
   PubMed Web of Science ®Google Scholar
• Hesse LM, Venkatakrishnan K, Court MH, et al. (2000). CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28:1176–83
   PubMed Web of Science ®Google Scholar
• Hesse LM, Greenblatt DJ, von Moltke LL, et al. (2006). Ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers. J Clin Pharmacol 46:567–76
   PubMed Web of Science ®Google Scholar
• Hesse LM, Sakai Y, Vishnuvardhan D, et al. (2003). Effect of bupropion on CYP2B6 and CYP3A4 catalytic activity, immunoreactive protein and mRNA levels in primary human hepatocytes: comparison with rifampicin. J Pharm Pharmacol 55:1229–39
   PubMed Web of Science ®Google Scholar
• Hogeland GW, Swindells S, McNabb JC, et al. (2007). Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects. Clin Pharmacol Ther 81:69–75
   PubMed Web of Science ®Google Scholar
• Joy MS, Frye RF, Stubbert K, et al. (2010). Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases. J Clin Pharmacol 50:714–20
   PubMed Web of Science ®Google Scholar
• Kennedy SH, McCann SM, Masellis M, et al. (2002). Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry 63:181–6
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Mitchell D, Coles R. (2008). Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity. J Clin Pharmacol 48:464–74
   PubMed Web of Science ®Google Scholar
• Kim H, Bae SK, Park SJ, et al. (2010). Effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion and its active metabolite, 4-hydroxybupropion, in healthy subjects. Br J Clin Pharmacol 70:126–31
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Klein C, Meineke I, et al. (2003). Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 13:619–26
   PubMedGoogle Scholar
• Kotlyar M, Brauer LH, Tracy TS, et al. (2005). Inhibition of CYP2D6 activity by bupropion. J Clin Psychopharmacol 25:226–9
   PubMed Web of Science ®Google Scholar
• Kustra R, Corrigan B, Dunn J, et al. (1999). Lack of effect of cimetidine on the pharmacokinetics of sustained-release bupropion. J Clin Pharmacol 39:1184–8
   PubMed Web of Science ®Google Scholar
• Laizure SC, DeVane CL. (1985). Stability of bupropion and its major metabolites in human plasma. Ther Drug Monit 7:447–50
   PubMed Web of Science ®Google Scholar
• Lei HP, Ji W, Lin J, et al. (2009). Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers. Br J Clin Pharmacol 68:201–6
   PubMed Web of Science ®Google Scholar
• Lei HP, Yu XY, Xie HT, et al. (2010). Effect of St. John's wort supplementation on the pharmacokinetics of bupropion in healthy male Chinese volunteers. Xenobiotica 40:275–81
   PubMed Web of Science ®Google Scholar
• Lewis BR, Aoun SL, Bernstein GA, et al. (2001). Pharmacokinetic interactions between cyclosporine and bupropion or methylphenidate. J Child Adolesc Psychopharmacol 11:193–8
   PubMed Web of Science ®Google Scholar
• Loboz KK, Gross AS, Williams KM, et al. (2006). Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Clin Pharmacol Ther 80:75–84
   PubMed Web of Science ®Google Scholar
• Masters AR, Gufford BT, Lu JB, et al. (2016a). Chiral plasma pharmacokinetics and urinary excretion of bupropion and metabolites in healthy volunteers. J Pharmacol Exp Ther 358:230–8
   PubMed Web of Science ®Google Scholar
• Masters AR, McCoy M, Jones DR, et al. (2016b). Stereoselective method to quantify bupropion and its three major metabolites, hydroxybupropion, erythro-dihydrobupropion, and threo-dihydrobupropion using HPLC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 1015-1016:201–8
   PubMed Web of Science ®Google Scholar
• Maxwell RA, Mehta NB, Tucker WE Jr, et al. (1981). Bupropion. In: Goldberg ME (ed) Pharmacological and biochemical properties of substances, American Pharmaceutical Association, Washington DC, pp 1–55
   Google Scholar
• Maxwell RA. (1985). The pharmacological rationale for bupropion. In: Pichot P, Berner P, Wolf R, Thau K ed. Psychiatry: the state of the art. New York: Plenum Press, 135–40
   Google Scholar
• McConathy J, Owens MJ. (2003). Stereochemistry in drug action. Prim Care Companion J Clin Psychiatry 5:70–3
   PubMedGoogle Scholar
• McGough JJ, Pataki CS, Suddath R. (2005). Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder. Expert Rev Neurother 5:437–41
   PubMedGoogle Scholar
• Melton ST, Wood JM, Kirkwood CK. (2005). Eszopiclone for insomnia. Ann Pharmacother 39:1659–66
   PubMed Web of Science ®Google Scholar
• Molden E, Garcia BH, Braathen P, et al. (2005). Co-prescription of cytochrome P450 2D6/3A4 inhibitor-substrate pairs in clinical practice. A retrospective analysis of data from Norwegian primary pharmacies. Eur J Clin Pharmacol 61:119–25
   PubMed Web of Science ®Google Scholar
• Molnari JC, Myers AL. (2012). Carbonyl reduction of bupropion in human liver. Xenobiotica 42:550–61
   PubMed Web of Science ®Google Scholar
• Musso DL, Mehta NB, Soroko FE, et al. (1993). Synthesis and evaluation of the antidepressant activity of the enantiomers of bupropion. Chirality 5:495–500
   PubMed Web of Science ®Google Scholar
• Newton TF, Roache JD, De La Garza R, II et al. (2005). Safety of intravenous methamphetamine administration during treatment with bupropion. Psychopharmacology (Berl) 182:426–35
   PubMed Web of Science ®Google Scholar
• Ngaimisi E, Mugusi S, Minzi O, et al. (2011). Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. Clin Pharmacol Ther 90:406–13
   PubMed Web of Science ®Google Scholar
• Nguyen LA, He H, Pham-Huy C. (2006). Chiral drugs: an overview. Int J Biomed Sci 2:85–100
   PubMedGoogle Scholar
• Odishaw J, Chen C. (2000). Effects of steady-state bupropion on the pharmacokinetics of lamotrigine in healthy subjects. Pharmacotherapy 20:1448–53
   PubMed Web of Science ®Google Scholar
• Ogu CC, Maxa JL. (2000). Drug interactions due to cytochrome P450. Proc (Bayl Univ Med Cent) 13:421–3
   PubMedGoogle Scholar
• Oh DA, Crean CS. (2015). Single-dose pharmacokinetics of bupropion hydrobromide and metabolites in healthy adolescent and adult subjects. Clin Pharmacol Drug Dev 4:346–53
   PubMed Web of Science ®Google Scholar
• Olbe L, Carlsson E, Lindberg P. (2003). A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat Rev Drug Discov 2:132–9
   PubMed Web of Science ®Google Scholar
• Park J, Vousden M, Brittain C, et al. (2010). Dose-related reduction in bupropion plasma concentrations by ritonavir. J Clin Pharmacol 50:1180–7
   PubMed Web of Science ®Google Scholar
• Pastoor D, Gobburu J. (2014). Clinical pharmacology review of escitalopram for the treatment of depression. Expert Opin Drug Metab Toxicol 10:121–8
   PubMed Web of Science ®Google Scholar
• Posner J, Bye A, Jeal S, et al. (1984). Alcohol and bupropion pharmacokinetics in healthy male volunteers. Eur J Clin Pharmacol 26:627–30
   PubMed Web of Science ®Google Scholar
• Qin WJ, Zhang W, Liu ZQ, et al. (2012). Rapid clinical induction of bupropion hydroxylation by metamizole in healthy Chinese men. Br J Clin Pharmacol 74:999–1004
   PubMed Web of Science ®Google Scholar
• Reese MJ, Wurm RM, Muir KT, et al. (2008). An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction. Drug. Metab Dispos 36:1198–201
   PubMed Web of Science ®Google Scholar
• Robertson SM, Maldarelli F, Natarajan V, et al. (2008). Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. J Acquir Immune Defic Syndr 49:513–9
   PubMed Web of Science ®Google Scholar
• Sager JE, Price LS, Isoherranen N. (2016). Stereoselective metabolism of bupropion to OH-bupropion, threohydrobupropion, erythrohydrobupropion, and 4'-OH-bupropion in vitro. Drug Metab Dispos 44:1709–19
   PubMed Web of Science ®Google Scholar
• Sager JE, Tripathy S, Price LS, et al. (2017). In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation. Biochem Pharmacol 123:85–96
   PubMed Web of Science ®Google Scholar
• Schmid Y, Rickli A, Schaffner A, et al. (2015). Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects. J Pharmacol Exp Ther 353:102–11
   PubMed Web of Science ®Google Scholar
• Schroeder DH. (1983). Metabolism and kinetics of bupropion. J Clin Psychiatry 44:79–81
   PubMed Web of Science ®Google Scholar
• Soroko FE, Mehta NB, Maxwell RA, et al. (1977). Bupropion hydrochloride ((+/-) alpha-t-butylamino-3-chloropropiophenone HCl): a novel antidepressant agent. J Pharm Pharmacol 29:767–70
   PubMed Web of Science ®Google Scholar
• Skarydova L, Tomanova R, Havlikova L, et al. (2014). Deeper insight into the reducing biotransformation of bupropion in the human liver. Drug Metab Pharmacokinet 29:177–84
   PubMed Web of Science ®Google Scholar
• Srinivas NR. (2016). Pharmacokinetic interaction of rifampicin with oral versus intravenous anticancer drugs: Challenges, dilemmas and paradoxical effects due to multiple mechanisms. Drugs R D 16:141–8
   PubMed Web of Science ®Google Scholar
• Stahl SM, Pradko JF, Haight BR, et al. (2004). A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry 6:159–66
   PubMedGoogle Scholar
• Strassburg CP, Barut A, Obermayer-Straub P, et al. (2001). Identification of cyclosporine A and tacrolimus glucuronidation in human liver and the gastrointestinal tract by a differentially expressed UDP-glucuronosyltransferase: UGT2B7. J Hepatol 34:865–72
   PubMed Web of Science ®Google Scholar
• Steuer AE, Schmidhauser C, Tingelhoff EH, et al. (2016). Impact of cytochrome P450 2D6 function on the chiral blood plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA) and its phase I and II metabolites in humans. PLoS One 11:e0150955
   PubMed Web of Science ®Google Scholar
• Szelenyi I, Geisslinger G, Polymeropoulos E, et al. (1998). The real gordian knot: racemic mixtures versus pure enantiomers. Drug News Perspect 11:139–60
   PubMedGoogle Scholar
• Todor I, Popa A, Neag M, et al. (2016). Evaluation of a potential metabolism-mediated drug-drug interaction between atomoxetine and bupropion in healthy volunteers. J Pharm Pharm Sci 19:198–207
   PubMed Web of Science ®Google Scholar
• Turpeinen M, Tolonen A, Uusitalo J, et al. (2005). Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther 77:553–9
   PubMed Web of Science ®Google Scholar
• USFDA. Drug Interaction Studies — Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations – Guidance for Industry (2012). https://www.fda.gov/downloads/drugs/guidances/ucm292362.pdf. Last Accessed on September 3, 2017
   Google Scholar
• Vakily M, Zhang W, Wu J, et al. (2009). Pharmacokinetics and pharmacodynamics of a known active PPI with a novel dual delayed release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Curr Med Res Opin 25:627–38
   PubMed Web of Science ®Google Scholar
• Wang X, Abdelrahman DR, Zharikova OL, et al. (2010). Bupropion metabolism by human placenta. Biochem Pharmacol 79:1684–90
   PubMed Web of Science ®Google Scholar
• Williams K, Lee E. (1985). Importance of drug enantiomers in clinical pharmacology. Drugs 30:333–54
   PubMed Web of Science ®Google Scholar
• Xu H, Loboz KK, Gross AS, et al. (2007). Stereoselective analysis of hydroxybupropion and application to drug interaction studies. Chirality 19:163–70
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Desai A, Goldwater R, et al. (2017). Pharmacokinetic effects of isavuconazole coadministration with the cytochrome P450 enzyme substrates bupropion, repaglinide, caffeine, dextromethorphan, and methadone in healthy subjects. Clin Pharmacol Drug Dev 6:54–65
   PubMed Web of Science ®Google Scholar
• Zadka Ł, Dziwota E, Olajossy M. (2016). Levomilnacipran-A successor of milnacipran with a higher noradrenergic selectivity. Acta Pol Pharm 73:285–9
   PubMed Web of Science ®Google Scholar